300239.SZ
东宝生物
SZSE · Healthcare · C 制造业 · CN
CNY 4.98
−5.50%Year over year
Reported trailing growth
- Revenue
- -10.0%
- EBITDA
- —
- EBIT
- -36.8%
- EPS
- -30.0%
- Free cash flow
- +320.0%
- Operating cash flow
- +300.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.6%
- EBITDA
- -9.9%
- EBIT
- -22.9%
- Net income
- -20.8%
- EPS
- -20.5%
- Free cash flow
- -32.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026